Quick Answer
Organogenesis Holdings Inc. reported R&D Expense of $44.54 million for fiscal year 2025.
Organogenesis Holdings Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $44.54M | -11.4% |
| 2024 | $50.27M | +13.3% |
| 2023 | $44.38M | +11.6% |
| 2022 | $39.76M | +29.3% |
| 2021 | $30.74M | +53.1% |
| 2020 | $20.09M | +35.7% |
| 2019 | $14.80M | +37.8% |
| 2018 | $10.74M | +18.5% |
| 2017 | $9.06M | +44.4% |
| 2016 | $6.28M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.22M | +27.8% | +27.2% |
| June 30, 2025 | $10.39M | -33.3% | -2.3% |
| March 31, 2025 | $10.64M | -16.9% | +2.9% |
| September 30, 2024 | $10.34M | -1.2% | -33.6% |
| June 30, 2024 | $15.59M | +42.5% | +21.7% |
| March 31, 2024 | $12.81M | +14.4% | +22.3% |
| September 30, 2023 | $10.47M | +9.3% | -4.3% |
| June 30, 2023 | $10.94M | +7.2% | -2.4% |
- Organogenesis Holdings Inc. showed a decrease of -11.4% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Organogenesis Holdings Inc.’s r&d expense has grown by 609.6% (from $6.28 million to $44.54 million).
- The most recent figure is from Organogenesis Holdings Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: